• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

GeoVax Labs, Inc.

Monday, June 03, 2024
CP
Immunology
GeoVax is a clinical-stage company developing novel therapies and vaccines for solid tumor cancers and infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. Our lead infectious disease candidate is GEO-CM04S1, a next-generation Covid-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated (i) as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized Covid-19 vaccines are insufficient, (ii) as a booster vaccine in patients with chronic lymphocytic leukemia (CLL), and (iii) as a more robust, durable Covid-19 booster among healthy patients who previously received the mRNA vaccines.
GeoVax Labs, Inc.
Company Website: http://www.geovax.com
Lead Product in Development: GEO-CM04S1 - Next Generation COVID-19 Vaccine Gedeptin - Therapy for Solid Tumor Cancers

Exchange

Nasdaq

Ticker

GOVX

Company HQ City

Smyrna

Company HQ State

GA

Company HQ Country

United States

CEO/Top Company Official

David Dodd

Development Phase of Primary Product

Phase II
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS